Showing posts with label prostate health. Show all posts
Showing posts with label prostate health. Show all posts

Monday, May 31, 2010

Purposeful Confusion?

UPDATE: 31 May 2010 (original post 6/19/09) -
The US Food and Drug Administration (FDA) lost its bid to overturn a health claim for selenium-containing dietary supplements last Thursday in the United States District Court for the District of Columbia. District Court Judge Ellen Huvelle ruled unconstitutional the FDA’s censorship of selenium dietary supplement claims relating to the reduction of cancer risk. Jonathan Emord of Emord & Associates on behalf of the plaintiffs in the case (including lead plaintiff ANH-USA; Durk Pearson and Sandy Shaw; and the Coalition to End FDA and FTC Censorship. The verdict, unless reversed on appeal, protects the First Amendment right of dietary supplement manufacturers to provide “qualified health claims”, which accurately communicate the state of science concerning dietary supplements. This is a remarkable seventh victory over the FDA by the Emord firm (six of which invalidated FDA health claim censorship).
The lawsuit was initiated last summer in response to the FDA’s 19th June 2009 decision to suppress selenium/cancer-risk reduction claims. Ten of the claims (all appealed by the plaintiffs) were held unconstitutionally censored. The plaintiffs expressed their belief that this violated their right to communicate truthful health information to the public. The judge found that the FDA had denied claims despite credible evidence supporting them and had thereby infringed on free speech.
Prior to this ruling the FDA required near conclusive scientific evidence for any nutrient claim. The judge ruled that so long as the claim is an accurate reflection of the state of science, the First Amendment protects it.
------------------------
UPDATE: 8 July - Please read what one of the good health organizations has to say about US censorship of scientifically-backed health claims for selenium.
--------------------------------------------------------------
UPDATE: 21 June - Government Intervening in Vitamin Industry
Other reports on Centrum can be found here at Natural Health News using SEARCH.
By Lorraine Heller
“Multivitamins and minerals were the subject of one quarter of Adverse Event Reports (AERs) filed with FDA in the first six months of last year, but this does not mean that this product category is problematic, says the American Herbal Products Association (AHPA).

The trade group analyzed 598 AERs received by the US Food and Drug Administration (FDA) between January 1 and June 30 2008, which highlighted potential adverse health effects of dietary supplement products.

However, although 25 per cent of these were for mainstream multivitamins and minerals, the findings must not be misinterpreted as identifying this as the most dangerous class of products, said Michael McGuffin, director AHPA.

‘This is not a cause and effect reporting system, it’s an association system. So although a large part of the AERs are linked to multivitamins, this does not mean that they are dangerous. It simply reflects usage patterns, and the most used dietary supplements are multivitamins,’ McGuffin told NutraIngredients-USA.com.

The AER reports were obtained by AHPA via Freedom of Information (FOI) requests with FDA. AHPA revealed its analysis of these reports at the recent SupplySide East trade show in Secaucus, New Jersey.

A number of supplement brands or products were repeatedly flagged up in the AERs. The most common single product reports were for:

• Total Body Formula (93 reports)
Bayer One a Day (all formulas) (81 reports)
• Centrum (all formulas) (25 reports)
• Flintstones Vitamins (all formulas) (24 reports)
• Mainstream calcium products (25 reports)

However, McGuffin again cautioned that this does not implicate these brands or products as being dangerous. It reflects the frequency of reporting by a select number of companies, which have put systematic reporting systems in place, he explained.

Out of the 600 AERs reviewed by AHPA, 44 percent were for combination products, 25 percent were for vitamins and minerals, 10 percent were for ‘other primary ingredients’ products, and 5 percent were for herbals.

The majority (almost 60 percent) of reports had been submitted by companies, while just under a third (30 percent) were submitted by consumers. Around 10 percent were sent in by health professionals.

The majority of cases (73 percent) were female consumers, and 54 percent of reports were for people aged between 50 and 79. Again, this reflects supplement usage, said McGuffin.”

Back in the 1980s there were daily publications of articles promoting the health benefit of selenium to protect men's prostate health. I've posted an ACS article from 2002 that shows this information below.

Several weeks ago I posted a discussion about a study that attacked selenium, showing mostly the ignorance of the people involved or interviewed regarding the effective form of selenium.

Generally inexpensive sodium selenite is the form used in synthetic products and it isn't always properly absorbed.

Now today Bayer is taking flack over its synthetic product, One-A-Day for Men. Well they should but not because of the concerns about synthetic vitamins, but for the fact that selenium - in the right form - is helpful for men's health and that of the prostate too.

Isn't it confusing? And do you really think medicine is progressing in providing prevention?
Group: Bayer ads mislead about prostate
Published: June 19, 2009 at 12:17 AM

A U.S. advocacy group notified Bayer Healthcare it will sue if the company continues to claim the selenium in its vitamins may reduce prostate cancer risk.

David Schardt, senior nutritionist at The Center for Science in the Public Interest in Washington, said advertisements and labels for One A Day Men's 50-plus Advantage and One A Day Men's Health Formula multivitamins claim "emerging research" suggests selenium may reduce the risk of prostate cancer.

However, leading prostate cancer researchers say there is scant evidence to support such a claim and have joined CSPI in urging the Federal Trade Commission to put an immediate stop to the claims, Schardt says.

"Bayer is exploiting men's fear of prostate cancer just to sell more pills," Schardt says in a statement. "The largest prostate cancer prevention trial has found that selenium is no more effective than a placebo. Bayer is ripping people off when it suggests otherwise in these dishonest ads."

A seven-year study found last year that selenium does not prevent prostate cancer in healthy men, Schardt says.

"We are aware of CSPI's complaint and are in the process of reviewing their allegations, in the meantime, we stand behind all claims made in support of our products, including One A Day multivitamins," Bayer officials said in a statement to WebMD. "The claims made in support of selenium are based on an FDA-approved qualified health claim."

© 2009 United Press International, Inc. All Rights Reserved.


Study Links Selenium and Age to Prostate Cancer Risk
Mineral May Reduce Risk
Article date: 2002/01/02 from the American cancer Society

A new study suggests that the mineral selenium may be important in reducing prostate cancer risk as men age, according to a report in the Journal of Urology (Vol. 166, No. 6: 2034-2038).

The research suggests that the older men get, the less selenium they are likely to have in their blood. This may explain why a man's chance of getting prostate cancer goes up as he ages, since there may be a relationship between very low selenium levels and increased risk of prostate cancer.

“Our results suggest the possibility that selenium supplements may be especially beneficial for older men,” said lead author, James D. Brooks, MD, assistant professor of urology at Stanford University Medical Center in Palo Alto, Calif.

Brooks cautioned that too much selenium can be toxic. The Institute of Medicine, a government organization that determines the recommended dietary allowances (RDA) of vitamins and minerals, suggests a daily selenium intake of 55 micrograms (mcg) daily for men over the age of 14. Selenium is found in organ meats (liver), seafood and vegetables (which depend on the selenium content of the soil). The maximum intake daily of selenium should not exceed 400 mcg daily from all sources.

Lowest Selenium Levels Raised Prostate Cancer Risk
Most Americans get enough selenium, Brooks noted, but in some areas of the US there is not much selenium in the soil, so there may not be enough in drinking water or in food.

To study the relationship between selenium and prostate cancer, Brooks and colleagues compared the levels of selenium in the blood from 52 men taken before they developed prostate cancer, to the selenium levels in blood given by 96 men who did not later develop prostate cancer.

These men were all part of an ongoing study called the Baltimore Longitudinal Study of Aging. They were examined about every two years over a long period of time.

Men with the least amount of blood selenium were four to five times more likely to develop prostate cancer in the next few years than those with more, the researchers found.

“There may be a threshold level — a certain amount needed to lower risk — but beyond that, adding more selenium may not offer any more protection,” said Brooks.

Study First to Link Selenium Levels, Risk and Age
An American Cancer Society (ACS) expert on cancer and nutrition said the Stanford study confirms earlier studies that show selenium may reduce risk of prostate cancer by as much as 60%, and it adds new information as well.

“This is the first study to show that selenium levels may drop as age increases, which could help explain why men’s chances of developing prostate cancer go up as they get older,” said Carmen Rodriguez, MD, a senior epidemiologist in the ACS department of Epidemiology and Surveillance Research.

But Rodriguez cautioned that the study had so few men in it that it’s difficult to be sure that conclusions from it are meaningful.

And she expressed concern that blood samples weren’t necessarily collected at the same ages from men who developed prostate cancer later and from those who didn’t, making the comparison not as equal as a better matched one.

Study Raises Questions Likely to be Addressed by SELECT Trial
Rodriguez said men interested in those questions and in learning more about reducing their risk of prostate cancer with selenium and/or vitamin E may want to participate in the SELECT Trial trial, or wait for its outcome, she noted.

“In the meantime, all men can use the knowledge we already have to keep their prostate cancer risk as low as possible by learning the risk factors for prostate cancer, and how to actively reduce their chances of developing the disease,” noted Rodriguez.


Men's Health

Thursday, December 10, 2009

Heady Hops helps in men's health

This is an interesting article for several reasons.

One, hops, the source of xanthohumol as mentioned in this article, has an estrogenic effect.  Usually in mainstream medicine the drug Lupron is used in the treatment of prostate cancer for its estrogenizing effect.

Perhaps taking hops herb and not beer might be an option, but if the doctors involved in this study had knowledge of herbs they might have drawn better concusions than suggesting finasteride.

Also evident is their ignorance about beer.  It contains such beneficial substances as IP6 and is much more nutrient rich. For the most part, German beer is really a food because it is not made in the manner of American beer. 

The hand-crafted microbrews from the US are more acceptable than mass produced cheap, fortified beers, the hallmark of Joe Six-Pack.  

Perhaps it is education that is needed in this conversation before it moves ahead.


Hops is high in B vitamins, magnesium, zinc* and a number of other minerals, along with plant growth hormones.  Zinc* is a key nutrient for the prostate and all glandular health.
Beer Ingredient Eyed in Prostate Cancer Prevention
By Steven Reinberg, HealthDay Reporter
WEDNESDAY, Dec. 9 (HealthDay News) -- An ingredient of beer may someday help ward off prostate cancer, new animal experiments suggest.
The compound in question, xanthohumol, is found in hops -- the bitter flavoring agent in beer -- and is known to block the male hormone testosterone, which plays a role in the development of prostate cancer.

"We hope that one day we can demonstrate that xanthohumol prevents prostate cancer development, first in animal models and then in humans, but we are just at the beginning," said lead researcher Clarissa Gerhauser, group leader of cancer chemoprevention in the division of epigenomics and cancer risk factors at the German Cancer Research Center in Heidelberg.

The findings were to be presented Dec. 9 at a conference of the American Association for Cancer Research in Houston.

Xanthohumol is a flavonoid, a group found in many plants, fruits, vegetables and spices. Studies of xanthohumol have shown that it blocks estrogen by binding to its receptor, which may lead to prevention of breast cancer, the researchers say. It's known that estrogen and testosterone receptors react in similar ways.

For this study, Gerhauser's team started with hormone-dependent prostate cancer cells and stimulated them with testosterone, which led to a massive secretion of prostate specific antigen (PSA).

"When we treated the cells together with testosterone and xanthohumol, PSA secretion was inhibited, and this was dependent on the dose of xanthohumol," Gerhauser said.

In additional experiments, the researchers found that xanthohumol binds with the receptor, preventing it from producing PSA.

Gerhauser's group found that when xanthohumol and testosterone were injected into castrated rats, xanthohumol blocked the effect of testosterone on the prostate, which potentially could lead to preventing prostate cancer.

"Although the prostate weights were not changed, xanthohumol still reduced the effects of hormone signaling, such as gene expression, measured in the prostate tissue," she said.

"Xanthohumol is a natural product, which blocks the effects of male hormone testosterone, and should therefore be investigated for prostate cancer prevention," she said.

Not everyone believes that beer looks like a potential solution to this disease, which affects one out of six American men and will kill more than 27,000 of them this year, according to the American Cancer Society.

Dr. Durado Brooks, director of prostate and colorectal cancer at the American Cancer Society, said that if beer could prevent prostate cancer, we would already see lower rates of it.

"Like a lot of findings, it's way too early. Showing that something works in a test tube and that you can impact rat prostates is a long way from demonstrating any sort of viability in humans," he said.

A better bet for men might be a drug (finasteride) which has been shown to reduce the risk of developing prostate cancer, Brooks said.

"Men need to understand that these drugs are not risk-free, but if a man is concerned about his prostate cancer risk then he should be aware that there are medicines out there that have been shown to be efficacious in decreasing the risk," he said.

Drinking a lot of beer is "not one of the things we recommend," Brooks said.

Sunday, February 8, 2009

Propecia and PSA

While there is quite a lot of evidence that the PSA is a very outdated and inaccurate test for this men's health concern, it contiues to be the most commonly used lab test for prostate cancer screening.

On 5 February, Johns Hopkins reports that the hair loss drug Propecia may inaccurately reflect PSA status.
Propecia and Your PSA February 5, 2009
By Johns Hopkins Health Alerts; www.johnshopkinshealthalerts.com

If you're a man who takes the hair-growth drug Propecia, you should let your doctor know before you have your next PSA test, as it could affect the accuracy of the results.

The prostate-specific antigen (PSA) test measures an enzyme produced almost exclusively by the glandular cells of the prostate. It is secreted during ejaculation into the prostatic ducts that empty into the urethra. PSA liquefies semen after ejaculation, promoting the release of sperm.

Normally, only very small amounts of PSA are present in the blood. But an abnormality of the prostate can disrupt the normal architecture of the gland and create an opening for PSA to pass into the bloodstream. Thus, high blood levels of PSA can indicate prostate problems, including cancer.

A blood test to measure levels of PSA was first approved by the U.S. Food and Drug Administration (FDA) in 1986 as a way to determine whether prostate cancer had been treated successfully and to monitor for its recurrence. Today, however, PSA tests are FDA approved for prostate cancer detection and are widely used to screen men for the disease.

Now research suggests that the hair-growth medication Propecia (finasteride) significantly lowers a man's PSA level, producing misleading results and potentially masking the presence of prostate cancer.

Propecia is the same medication as Proscar, which is used to control benign prostatic hyperplasia (BPH). The difference is the dosage -- 5 mg per day for Proscar vs. 1 mg for Propecia. Proscar is known to artificially lower PSA levels by about half, and doctors interpreting PSA results in these men compensate by doubling the PSA value. But Propecia's impact on PSA level has not been formally studied until now.

The researchers in the study which was reported in the journal Lancet Oncology (Volume 8, page 21) assigned 355 men age 40-60 to take either Propecia or a placebo (inactive pill) for 48 weeks. For analysis purposes, the men were grouped by age: 40-49 and 50-60. By the end of the study period, PSA levels among men in the younger group had dropped by an average of 40%; in the older group, PSA declined by an average of 50%. Among men taking the placebo, the PSA levels of the younger men had not changed, and the levels of the older men had risen by an average of 13%.

Bottom Line: If you use Propecia, be sure to let your physician know so that your PSA results can be adjusted accordingly.
© 2009 Medletter Associates, LLC. All rights reserved.

Monday, November 10, 2008

Old News Makes the Rounds Again

I'm slowly updating my original web site that went on-line in the early 1990s. I'm working on it a few pages at a time. I do hope to have some help from two students at one of my colleges very soon.

While updating I found this news from early 2005. I'm sure it was known well before that time. Now in 2008, are we there yet. Instant replay yes, but where was implementation back in the day?

D. Mail 3.8.05 "VITAMIN D CAN REDUCE PROSTATE RISK"
A new study reveals Vitamin D cuts a man's risk of prostate cancer by almost half. Researchers in Boston analysed blood & found men with the highest vit D had a 45% less risk of prostate cancer. They believe vit D inhibits cell growth & has anti-cancer properties. Vit D is lower in older men who are most prone to prostate cancer. The recommended daily amount of vit D is 400 iu but some experts think that is low.


And today we learn that this remarkable (fat soluable) vitamin might protect from low level radiation.

Our center offers high quality, high dose Vitamin D in several potencies. All profits help support our work.

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Macys Printable Coupons